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Introduction 
 
 Plasmodium enters the blood stream of a 
mammalian host via a bite by an infected Anopheles 
mosquito. Translocation to the liver and introduction 
into a hepatocyte is a critical step for infectivity of the 
malaria parasite. Entry of the parasite follows two 
distinct pathways: rupturing of the hepatocyte 
membrane by migration or by the adhesion, 
internalization, and formation of a vacuole within the 
hepatocyte (Silvie et. al., 2004b). Only the latter 
pathway is necessary for the differentiation and 
proliferation of the blood-stage pathogen.  
My focus will be primarily on the interaction of 
cell-surface proteins between the hepatocyte and the 
parasite. There are two well-studied proteins secreted 
by apical micronemes (i.e. vesicles at the anterior tip of 
the protozoan which secrete enzymes for parasite 
entry): the circumsporozoite protein (CSP) and the 
thrombospodin-related adhesive protein (TRAP; Silvie 
et. al., 2004b). The exocytosis of CSP and TRAP from 
micronemes within the parasite is dependent on the 
transient increase of intracellular calcium. Once the 
micronemes are excreted, CSP and TRAP localize to 
the membrane of Plasmodium. This process exposes 
CSP and TRAP to interact with hepatocyte cell-surface 
proteins, thus allowing the internalization and infection 
of the parasite by an unknown mechanism. A 
parasitophorous vacuole (PV) is formed after 
internalization, which is required for the differentiation of 
the exoerythrocytic form (EEF; Silvie et. al., 2004b).   
CSP has many roles in the life of 
Plasmodium including sporozoite formation in oocysts, 
gliding locomotion, hepatocyte invasion, as well as 
inhibition of ribosomes (Menard, 2000). During gliding 
motility, CSP is shed from the cell surface. Previous 
studies have used monoclonal antibodies (mAb) 
against CSP and prevented locomotion of Plasmodium, 
thereby preventing infection (Mota et. al., 2002b). 
CSP’s array of functions present many therapeutic 
targets. Plasmodium falciparum CSP vaccines have 
had some triumph in human trials, yet effective blood 
titer of antibody were not sustained (Gantt et. al., 2000). 
Yet, success has not been observed with TRAP 
because its exposure is limited to the intimate contact 
with unknown hepatocyte cell-surface proteins. CSP, on 
the other hand, is evenly distributed on Plasmodium, 
allowing for more binding sites on hepatocytes for 
antibody neutralization.  
            Much success has been achieved with the study 
of TRAP and CSP. These accomplishments give basis 
for further study of other parasite-surface proteins. 
Apical Membrane Antigen 1 (AMA-1) is an understudied 
protein also found within micronemes and is released 
onto the cell-surface with the advent of intracellular 
calcium. Silvie and colleagues (2004a) have inhibited 
HepG2 cell Plasmodium falciparum infectivity with a  
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mAb against AMA-1. I propose to perform a similar 
experiment using a primary hepatocyte cell culture from 
mice with Plasmodium yoelii. Further understanding of 
AMA-1 role in parasite entry will allow us to develop a 
potential synergistic vaccine with a CSP inoculum in a 
murine model, which cannot be immediately done in 
HepG2 cell cultures (Gantt et. al., 2000).   
 
Aims 
 
 Based on evidence seen in HepG2 cells, I will 
test the efficacy of anti-AMA-1 mAb in mice to 
neutralize the infectivity of Plasmodium yoelii in primary 
hepatocyte cultures from wild-type mice. Previously, 
HepG2 cells were protected against Plasmodium 
infectivity with increasing concentrations of anti-AMA-1 
mAb (Silvie et. al., 2004a).   
               Secondly, I will test the infectivity of P. yoelli 
on primary hepatocytes from mice preincubated with 
anti-AMA-1 mAb and treated 3 hours post sporozoite 
introduction. In the past, HepG2 cells were found 
susceptible to Plasmodium infection after this 
procedure (Silvie et. al., 2004a).  . This study will further 
verify the necessity of the AMA-1 protein for sporozoite 
entry into hepatocytes and subsequent infection.    
 
Experimental Procedure 
 
 Firstly, I hypothesize that the anti-AMA-1 
mAb will prevent Plasmodium yoelii entry and infection 
of wild-type mouse hepatocytes as noted in HepG2 
cells (Silvie et. al., 2004). The anti-AMA-1 mAb for P. 
yoelii will be obtained as described in Silvie and 
colleagues (2004a). Note, the ectodomain of AMA-1 is 
conserved across many Plasmodium species including 
parasites that infect rats. Primary hepatocyte cultures 
from wild-type mice will be treated with anti-AMA-1 mAb 
and inculated with P. yoelii sporozoites in the presence 
of rhodamine-labeled dextran (Silvie et. al., 2003c). 
Dextran-positve cells will indicate the migration of 
sporozoites without parasitophorous vacuole (PV) 
formation. Dextran-negative cells will indicate PV 
formation without disruption of the hepatocyte 
membrane.  
               I believe that AMA-1 is necessary for 
Plasmodium invasion and proliferation in the 
hepatocyte, thus treated cells should be Dextran-
positive (i.e. noting the migration of parasites thru 
hepatocytes without PV formation due to mAb 
competitive inhibition). One pitfall may be the presence 
of calcium in this procedure. Calcium has not been 
added to induce exposure of the AMA-1 protein from 
the microneme. A calcium ionophore may be necessary 
to trigger the apical exocytosis upon invasion (Mota et. 
al, 2002a). A green phycoerythrin labeled monoclonal 
antibody will be used to stain for the presence of the 
PV, or circumsporozoite proteins (CSP) as described in 
Silvie and colleagues (2003c) thus noting infectious 
entry. A culture of P. yoelii infected cells not treated 
with the anti-AMA-1 mAb will serve as the control for 
this experiment. The control cells should be both 
Dextran-negative and Dextran-positive because of the 
two invasion pathways observed by Plasmodium: 
migration and infectious entry. 
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               Secondly, I will further verify the role of AMA-1 
in Plasmodium infectivity by preincubating a primary 
wild-type mouse culture with anti-AMA-1 mAb and P. 
yoelii. Microscopy as well as immunofluorescence 
decribed above will be used to assess the percentage 
of exoerythrocytic forms (i.e. blood stage pathogens) 
within hepatocyte tissue. This experiment is significant 
because it will assess the level of toxicity induced by 
the antibody treatment on P. yoelli. I hypothesize no 
significant induced toxicity of P. yoelii. This will serve as 
the control for the following experiment. Primary culture, 
wild-type mouse, and hepatocytes will be inoculated 
with P. yoeli,i which will be incubated for 3 hours. After 
this time period, anti-AMA-1 mAb will be used to treat 
the infected hepatocytes. The percent of EEFs will be 
monitored for a 48 hour period.  
               I hypothesize a significant increase of EEFs in 
comparison to the control. If the result is positive, this 
experiment will confirm the necessity of the AMA-1 
protein for invasion and formation of a PV for 
Plasmodium proliferation. If negative, the AMA-1 
protein may be operating in an undetermined 
mechanism. This mechanism may be similar to the 
TRAP protein, in that, exposure of AMA-1 from the 
apical complex occurs only after the influx of calcium 
and close proximity to the hepatocyte. Thus, the 
antibody treatment may not present a satisfactory way 
to bind AMA-1 because of the discrete affinity of AMA-1 
to unknown cell-surface proteins on the hepatocyte. 
This proposed model contrasts the uniform 
arrangement of CSP around Plasmodium.  
 
Conclusion 
                                                                                                                            
The above experiments have been used 
previously to elucidate the significance of 
parasitophorous vacuole formation for infectivity of 
Plasmodium in Silvie and colleagues (2003c). With the 
conclusion of the above research, we will have further 
characterized the function of an additional microneme 
protein in context with sporozoite infectivity. In addition 
to TRAP and CSP, AMA-1 may serve as a putative 
receptor for sporozoite invasion and be used to 
construct a vaccine similar to the human CSP vaccine. 
A combined CSP/AMA-1 immunization may prove to 
have synergistic effects on Plasmodium protection 
(Gantt et. al., 2000).  
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